XML 51 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Cash flows from operating activities:      
Net (loss) income $ (24,835) [1],[2] $ (8,628) [3] $ 8,753
Adjustments to reconcile net (loss) income to cash flows (used in) provided by operating activities:      
Impairment of intangible assets 14,830    
Amortization of intangible assets 2,037 3,302 3,289
Depreciation of property and equipment 190 53 37
Change in fair value of derivatives (170) (1,140) 339
Amortization of bond premium on marketable securities 264 189 1
Stock-based compensation 1,411 2,052 1,495
Deferred income tax benefit (13) (209)  
Changes in operating assets and liabilities:      
Accounts and other receivables (128) 285 (290)
Prepaid expenses and other current assets (44) (36) 52
Accounts payable 64 (64) 110
Accrued expenses (712) 146 (360)
Deferred revenue (1,895) 880 (3,527)
Net cash (used in) provided by operating activities (9,001) (3,170) 9,899
Cash flows from investing activities:      
Purchases of marketable securities (15,392) (15,963) (2,054)
Maturities of marketable securities 15,299 6,598  
Proceeds from sales of marketable securities 1,104    
Purchases of property and equipment (405) (133) (15)
Net cash provided by (used in) investing activities 606 (9,498) (2,069)
Cash flows from financing activities:      
Proceeds from issuance of stock, net of issuance costs   10,043  
Proceeds from exercise of stock options and warrants 114 17 802
Net cash provided by financing activities 114 10,060 802
Effect of foreign exchange rate changes on cash and cash equivalents (6) 6 (17)
Net (decrease) increase in cash and cash equivalents (8,287) (2,602) 8,615
Cash and cash equivalents at beginning of year 12,912 15,514 6,899
Cash and cash equivalents at end of year 4,625 12,912 15,514
Supplemental disclosure of cash flow information:      
Cash paid for income taxes   $ 56 $ 266
[1] Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)
[2] Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).
[3] Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).